Could a Starch-Based drug clean toxins from dialysis Patients' blood?
NCT ID NCT07653711
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether a drug called coated aldehyde oxystarch (Xiqing) can reduce protein-bound uremic toxins in adults with end-stage renal disease who are on dialysis. Participants take the drug three times daily for three months. Researchers measure toxin levels in the blood before and after treatment to see if they drop.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Coated Aldehyde Oxystarch (Xiqing)
- What this could lead to
- If it works, this could offer a new way to reduce harmful toxins in dialysis patients, potentially improving their health and quality of life.
- What could go wrong
- This is a small, early exploratory trial with only 30 participants, so results may not apply broadly. The treatment may not lower toxins enough to make a difference, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years, no restriction on sex or ethnicity. * Receiving maintenance dialysis for at least 3 months, with dialysis regimen remaining unchanged during the trial period. * If taking other medications that do not interfere with gut microbiota prior to enrollment, they must have been stable for at least 1 month and the regimen must remain unchanged during the trial. * Ability to understand and voluntarily sign the informed consent form. Exclusion Criteria: * Known allergy to Coated Aldehyde Oxystarch. * History of or planned kidney transplantation within 6 months, or change in dialysis regimen. * Use of medications or supplements that may affect gut microbiota (e.g., antibiotics, probiotics, prebiotics, laxatives) within the past 3 months. * Diagnosis of serious gastrointestinal diseases, including gastrointestinal bleeding, colitis, inflammatory bowel disease, irritable bowel syndrome, history of intestinal obstruction, history of gastrectomy or duodenectomy. * History of cardiovascular or cerebrovascular events within 3 months prior to screening, including hospitalization for stroke, myocardial infarction, unstable angina, congestive heart failure; severe valvular stenosis, uncontrolled atrial fibrillation or arrhythmia; QTc interval \>500 ms on repeated ECG. * Concurrent severe primary diseases of cardiovascular, cerebrovascular, hepatic, hematopoietic systems, or other known life-threatening diseases (e.g., malignancy, AIDS), or patients with mental or legal disabilities. * Investigator judges life expectancy ≤6 months. * Inability to maintain stable dietary habits during the study period. * Inability to maintain original dialysis regimen during the study period. * Use of Chinese patent medicines for kidney disease (e.g., Shenkang Injection, Haikun Shenxi Capsule, Shenshuaining, Tripterygium preparations, Niaoduqing Granules) within 1 month prior to enrollment. * Participation in another clinical trial within the past 1 month. * Intellectual disability, psychiatric disorders, or suspected/confirmed history of alcohol or drug abuse that may affect compliance. * Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for End stage renal disease on dialysis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a special filter help dialysis remove toxins it usually misses?
- Can hidden heart rhythms explain dialysis risks?
- Can a Brain-Targeting drug silence the relentless itch of dialysis?
- Can a new graft keep dialysis access working longer?
- Can a diabetes drug boost dialysis efficiency for kidney patients?
- New study peers inside lungs during Clot-Busting procedure